Quiz|Articles|August 25, 2024
Targeted Pulse Quiz: August 25
Author(s)Morgan Bayer
Fact checked by: Tony Berberabe, MPH
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Advertisement
Ready for the challenge? Let’s begin!
Question 1 of 4: What recent status did fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) receive from the FDA?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 LAGOON Trial Fails to Confirm Survival Benefit of Lurbinectedin in Relapsed SCLC
2
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
3
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
4
The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports
5



































